A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
NiKang Therapeutics, Inc.
Pliant Therapeutics, Inc.
Eli Lilly and Company
MOMA Therapeutics
Eli Lilly and Company
Eli Lilly and Company
Kivu Bioscience Inc.
MOMA Therapeutics
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Revolution Medicines, Inc.
USWM, LLC (dba US WorldMeds)
Conjupro Biotherapeutics, Inc.
National Cancer Institute (NCI)
GlaxoSmithKline
Institut Paoli-Calmettes
Orano Med LLC
Alterome Therapeutics, Inc.
ViroMissile, Inc.
Pfizer
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
MacroGenics
University of Colorado, Denver
UNC Lineberger Comprehensive Cancer Center
Solve Therapeutics
University of Washington
OncoNano Medicine, Inc.
City of Hope Medical Center
Sairopa B.V.
City of Hope Medical Center
University Health Network, Toronto
Therorna
National Cancer Institute (NCI)
Incyte Corporation
NiKang Therapeutics, Inc.
Nurix Therapeutics, Inc.
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Pfizer
Context Therapeutics Inc.
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Lyell Immunopharma, Inc.
NextPoint Therapeutics, Inc.
M.D. Anderson Cancer Center